PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2017-12-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT02974374
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT02969044
- Locations
- 🇺🇸
Clayton Medical Associates, PC, Saint Louis, Missouri, United States
🇺🇸California Medical Research Associates Inc., Northridge, California, United States
🇺🇸Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT02969018
- Locations
- 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇨🇦Lynderm Research Inc, Markham, Ontario, Canada
🇺🇸Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 319
- Registration Number
- NCT02958865
- Locations
- 🇺🇸
Dothan Surgery Center, Dothan, Alabama, United States
🇺🇸Gut P.C., dba Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Southern California Research Institute Medical Group/West Gastroenterology Medical Group/Airport En-, Los Angeles, California, United States
Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia
- Conditions
- Non-Interventional Study
- Interventions
- Other: Overall satisfaction questionnaires of home use of Nivestim
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 171
- Registration Number
- NCT02956967
- Locations
- 🇩🇪
Office of Albrecht Kretzschmar, Leipzig, Germany
🇩🇪Office of Nidal Gazawi, Leipzig, Germany
🇩🇪Campus Charite Mitte, Med. Klinik m. Schwerpunkt Haematologie und Onkologie, Berlin, Germany
A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: MultivalentBiological: Tdap
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 66
- Registration Number
- NCT02955160
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT02954653
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Banner-University Medical Center Tucson, Tucson, Arizona, United States
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Other: Chemoradiation
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 697
- Registration Number
- NCT02952586
- Locations
- 🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States
🇺🇸University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Biological: AvelumabBiological: UtomilumabBiological: RituximabOther: Azacitidine
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT02951156
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇮🇹Istituto Clinico Humanitas, Rozzano, MI, Italy
🇺🇸City of Hope, Duarte, California, United States
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
- Conditions
- Primary Hyperlipidemia or Mixed Dyslipidemia
- Interventions
- Biological: BococizumabDrug: Placebo
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02947334
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China